1. Home
  2. MYO vs KPTI Comparison

MYO vs KPTI Comparison

Compare MYO & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYO
  • KPTI
  • Stock Information
  • Founded
  • MYO 2004
  • KPTI 2008
  • Country
  • MYO United States
  • KPTI United States
  • Employees
  • MYO N/A
  • KPTI N/A
  • Industry
  • MYO Industrial Specialties
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • MYO Health Care
  • KPTI Health Care
  • Exchange
  • MYO Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • MYO 44.6M
  • KPTI 44.5M
  • IPO Year
  • MYO 2017
  • KPTI 2013
  • Fundamental
  • Price
  • MYO $0.96
  • KPTI $6.50
  • Analyst Decision
  • MYO Strong Buy
  • KPTI Buy
  • Analyst Count
  • MYO 3
  • KPTI 6
  • Target Price
  • MYO $8.17
  • KPTI $39.80
  • AVG Volume (30 Days)
  • MYO 2.1M
  • KPTI 213.1K
  • Earning Date
  • MYO 11-05-2025
  • KPTI 11-04-2025
  • Dividend Yield
  • MYO N/A
  • KPTI N/A
  • EPS Growth
  • MYO N/A
  • KPTI N/A
  • EPS
  • MYO N/A
  • KPTI N/A
  • Revenue
  • MYO $40,760,091.00
  • KPTI $137,269,000.00
  • Revenue This Year
  • MYO $25.69
  • KPTI $3.67
  • Revenue Next Year
  • MYO $23.52
  • KPTI $9.40
  • P/E Ratio
  • MYO N/A
  • KPTI N/A
  • Revenue Growth
  • MYO 93.08
  • KPTI N/A
  • 52 Week Low
  • MYO $0.92
  • KPTI $3.51
  • 52 Week High
  • MYO $7.17
  • KPTI $16.95
  • Technical
  • Relative Strength Index (RSI)
  • MYO 24.94
  • KPTI 56.15
  • Support Level
  • MYO $0.96
  • KPTI $5.70
  • Resistance Level
  • MYO $1.17
  • KPTI $7.17
  • Average True Range (ATR)
  • MYO 0.07
  • KPTI 0.63
  • MACD
  • MYO 0.03
  • KPTI -0.09
  • Stochastic Oscillator
  • MYO 5.82
  • KPTI 33.67

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: